Phase 3 Ankylosing Spondylitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
If you have a fever of unknown cause:
- You have been ill for more than 3 weeks
- You have had a high temperature (above 38.3°C) on more than 3 occasions, or blood tests have shown signs of inflammation on more than 3 occasions
- Doctors have not been able to find the cause despite standard initial tests
If you may have a condition called IgG4-related disease (IgG4-RD):
- An experienced specialist strongly suspects you have this condition based on your symptoms, examination, and test results
- You have recently been diagnosed with IgG4-RD through a tissue sample (biopsy) and need further scans to check how far the condition has spread
- You have a previously confirmed diagnosis of IgG4-RD and a specialist believes it has come back
If you may have a condition causing inflammatory back pain (axial spondyloarthropathy):
- An experienced rheumatology specialist strongly suspects you have this condition based on symptoms such as back pain lasting more than 3 months, stiffness in the morning, pain that improves with movement but worsens with rest, pain at night, and onset before age 45
- You still have ongoing inflammatory back pain after trying 2 different types of standard anti-inflammatory painkillers (each tried for 2–4 weeks), and you are therefore being considered for a stronger type of medication called biological therapy
Who may not be able to join:
- You are not able to fully understand the study or are unwilling or unable to take part in all required procedures
- You have another condition or disorder that the study doctor feels could put your safety at risk or affect your ability to follow the study plan
- You are currently receiving or have previously received a treatment that the study doctor feels could affect your safety or the reliability of the trial results
- You are pregnant (a urine pregnancy test will be done if applicable), breastfeeding, planning to become pregnant, or you could become pregnant and are not using a reliable, highly effective form of contraception (confirm with trial site for specific accepted methods)
- You are already taking part in another clinical trial involving an experimental medicine or device, unless the study team considers both trials to be compatible
- You have taken part in a scientific study in the last 12 months where the experimental procedures exposed you to more than 1 mSv of radiation
- You have a known allergy or sensitivity to the imaging agent used in this trial, called [¹⁸F]AlF-FAPI-74, or any of its ingredients
- You have already started active treatment for the condition being studied
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +0032 16 34 37 15
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
FUO/IUO: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is equivalent or superior to the current gold standard, [18F] FDG PET/CT, in contributing to the final diagnosis (non-inferiority study with non-inferiority limit (10%); IgG4-RD: Demonstrate that the diagnostic performance of [18F]AlF-FAPI-74 PET/CT is superior to [18F]FDG PET/CT, in patients with suspicion of IgG4-RD and assessment of disease extent in patients with confirmed or relapsed IgG4-RD.; Axial Spondyloarthritis: evaluate the diagnostic accuracy of [18F]AlF-FAPI-74 PET/CT in differentiating inflammatory b...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.